Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy [0.03%]
作者勘误：VIALE-C的6个月随访显示，在无法进行强化化疗且未经治疗的AML患者中，疗效得到了改善并持续了一段时间
Andrew H Wei,Panayiotis Panayiotidis,Pau Montesinos et al.
Andrew H Wei et al.
Published Erratum
Blood cancer journal. 2021 Oct 26;11(10):171. DOI:10.1038/s41408-021-00565-6 2021
Yael N Shapiro,Jeffrey M Peppercorn,Andrew J Yee et al.
Yael N Shapiro et al.
As the prognosis for multiple myeloma (MM) has significantly improved and patients remain on therapy longer, there is a need for supportive care interventions to optimize patient quality of life (QOL) and functional status over the course o...
Clinical and molecular correlates from a predominantly adult cohort of patients with short telomere lengths [0.03%]
具有短端粒长度的成年患者群体的临床和分子特征分析
Abhishek A Mangaonkar,Alejandro Ferrer,Filippo Pinto E Vairo et al.
Abhishek A Mangaonkar et al.
Multicenter Study
Blood cancer journal. 2021 Oct 22;11(10):170. DOI:10.1038/s41408-021-00564-7 2021
Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma [0.03%]
伊沙妥昔单抗联合泊马度胺和地塞米松在多发性骨髓瘤中的抗体干扰和反应动力学研究
Cyrille Hulin,Meral Beksac,Hugh J Goodman et al.
Cyrille Hulin et al.
Clinical Trial
Blood cancer journal. 2021 Oct 20;11(10):169. DOI:10.1038/s41408-021-00562-9 2021
Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy [0.03%]
多发性骨髓瘤患者抗-BCMA嵌合抗原受体疗法长期随访中的病毒感染/复发
Di Wang,Xia Mao,Yimei Que et al.
Di Wang et al.
Clinical Trial
Blood cancer journal. 2021 Oct 18;11(10):168. DOI:10.1038/s41408-021-00563-8 2021
Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants [0.03%]
具有少见维甲酸受体-α(RARA)融合变异的急性髓系白血病的特征和预后
Laura Cicconi,Anna Maria Testi,Pau Montesinos et al.
Laura Cicconi et al.
Dysregulated APOBEC3G causes DNA damage and promotes genomic instability in multiple myeloma [0.03%]
APOBEC3G的失调会导致多发性骨髓瘤中的DNA损伤并促进基因组不稳定性的增加
Srikanth Talluri,Mehmet K Samur,Leutz Buon et al.
Srikanth Talluri et al.
Multiple myeloma (MM) is a heterogeneous disease characterized by significant genomic instability. Recently, a causal role for the AID/APOBEC deaminases in inducing somatic mutations in myeloma has been reported. We have identified APOBEC/A...
Author Correction: The biological significance of histone modifiers in multiple myeloma: clinical applications [0.03%]
作者勘误：多发性骨髓瘤中组蛋白修饰物的生物意义：临床应用
Hiroto Ohguchi,Teru Hideshima,Kenneth C Anderson
Hiroto Ohguchi
Published Erratum
Blood cancer journal. 2021 Oct 6;11(10):165. DOI:10.1038/s41408-021-00559-4 2021
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia [0.03%]
CPX-351作为急性髓系白血病患者一线治疗的实际经验
Christina Rautenberg,Friedrich Stölzel,Christoph Röllig et al.
Christina Rautenberg et al.
To investigate the efficacy and toxicities of CPX-351 outside a clinical trial, we analyzed 188 patients (median age 65 years, range 26-80) treated for therapy-related acute myeloid leukemia (t-AML, 29%) or AML with myelodysplasia-related c...
Clinical Trial
Blood cancer journal. 2021 Oct 4;11(10):164. DOI:10.1038/s41408-021-00558-5 2021
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150) [0.03%]
VIALE-C 6个月的随访显示，在无法进行强化化疗的未经治疗的AML患者中，疗效得到了改善并具有持久性（141/150）
Andrew H Wei,Panayiotis Panayiotidis,Pau Montesinos et al.
Andrew H Wei et al.
VIALE-C compared the safety and efficacy of venetoclax or placebo plus low-dose cytarabine (+LDAC) in patients with untreated AML ineligible for intensive chemotherapy. Overall, 211 patients were enrolled (n = 143, venetoclax; n = 68, place...
Clinical Trial
Blood cancer journal. 2021 Oct 1;11(10):163. DOI:10.1038/s41408-021-00555-8 2021